argenx Forte Biosciences acquisition: What the $2.2bn FB102 deal means for immunology
argenx is buying Forte Biosciences for $2.2bn to secure FB102. See why early vitiligo and celiac data make Phase 2 execution decisive.
Pharma & Biotech